{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:49:00Z","timestamp":1792450140886,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jaad.2024.10.045","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T06:28:23Z","timestamp":1730615303000},"page":"588-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.1016","volume":"92","author":[{"given":"Lydia","family":"Cassard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameson","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Piliang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2024.10.045_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40257-020-00557-5","article-title":"Hormonal contraceptives and dermatology","volume":"22","author":"Williams","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.045_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaad.2017.12.051","article-title":"Incidence of androgenic dermatologic side effects following placement of a levonorgestrel intrauterine device for menorrhagia: a survey-based study","volume":"79","author":"Lullo","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.045_bib3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jaad.2022.01.023","article-title":"Correlations between hormonal intrauterine devices and androgenic skin conditions: a retrospective cohort study","volume":"87","author":"Munjal","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.045_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/AOG.0000000000003034","article-title":"Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system","volume":"133","author":"Teal","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.045_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.contraception.2015.04.006","article-title":"Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system","volume":"92","author":"Eisenberg","year":"2015","journal-title":"Contraception"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224030615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224030615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T03:40:06Z","timestamp":1739936406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224030615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0190962224030615"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.045","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}